OmniAb (OABI) Stock Price, News & Analysis

Company Overview

OmniAb, Inc. (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021. Since its inception, the company has invested in multiple transgenic platforms—including OmniRat®, OmniMouse®, OmniChicken® and OmniClic®—to generate human and humanized antibodies with favorable developability profiles. These platforms are complemented by advanced bioinformatics and automation tools designed to streamline candidate selection and reduce time to clinic.

OmniAb serves a global client base of biotechnology and pharmaceutical companies, supporting antibody programs from early discovery through preclinical validation. The company maintains research facilities in North America and Europe, and its business development team collaborates closely with partners to tailor project portfolios and milestone-based arrangements.

Led by a management team with deep expertise in protein engineering, translational research and commercial strategy, OmniAb continues to expand its platform capabilities and strategic alliances. The company’s integrated approach aims to address key challenges in antibody discovery, including immunogenicity, manufacturability and target specificity, to deliver next-generation biologic therapeutics.

Key Stats

• Today's Range: $2.55 to $2.63
• 50-Day Range: $1.36 to $2.65
• 52-Week Range: $1.22 to $2.73
• Volume: 435,128 shs
• Average Volume: 521,497 shs
• Market Capitalization: $378.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

OmniAb Stock Analysis - MarketRank™

OmniAb scored higher than 54% of companies evaluated by MarketBeat, and ranked 592nd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Hold

Consensus Rating

OmniAb has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

OmniAb has a consensus price target of $3.00, representing about 15.6% upside from its current price of $2.60.

Amount of Analyst Coverage

OmniAb has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OmniAb are expected to grow in the coming year, from ($0.40) to ($0.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OmniAb is -5.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OmniAb is -5.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OmniAb has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.77% of the float of OmniAb has been sold short.

Short Interest Ratio / Days to Cover

OmniAb has a short interest ratio ("days to cover") of 4.27.

Change versus previous month

Short interest in OmniAb has recently decreased by 6.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OmniAb does not currently pay a dividend.

Dividend Growth

OmniAb does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.93

News Sentiment

OmniAb has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for OmniAb this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 2 people have added OmniAb to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, OmniAb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,638.00 in company stock.

Percentage Held by Insiders

9.80% of the stock of OmniAb is held by insiders.

Percentage Held by Institutions

72.08% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 5/28/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:OABI
• CIK: 1846253
• Web: www.omniab.com
• Phone: 510-250-7800
• Fax: N/A
• Employees: 7
• Year Founded: 2012

Price Target and Rating

• Average Price Target for OmniAb: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +14.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$64.78 million
• Net Margins: -187.59%
• Pretax Margin: -190.93%
• Return on Equity: -20.31%
• Return on Assets: -18.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.80
• Quick Ratio: 4.80

Sales & Book Value

• Annual Sales: $28.94 million
• Price / Sales: 13.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.81 per share
• Price / Book: 1.44

Miscellaneous

• Outstanding Shares: 144,783,000
• Free Float: 130,594,000
• Market Cap: $378.46 million
• Optionable: Optionable
• Beta: 0.07